Charles Ross & Son Appoints New Vice President of Sales
Ken Langhorn, who joined the company in February 1998, will assume the position.
Charles Ross & Son, a mixing equipment, blenders, dispersers, and dryers manufacturing company located in Hauppauge, NY, announced the appointment of Ken Langhorn as the new vice president of sales on Nov. 15, 2019.
According to a company press release, Langhorn joined the company in February 1998 as a lab assistant in the company's Test and Development Center after graduating with a Bachelor of Science degree from Stony Brook University in Stony Brook, NY. There, he worked on the company’s HV Blades, Mega Shear, and Inline SLIM technologies. Langhorn was then promoted to product manager of high shear mixers, high speed dispersers, multi-shaft mixers, and three roll mills in December 1999.
In June 2006, Langhorn was named technical director and managed the Test and Development Center where he worked with customers on more than 150 tests annually and provided support to sales teams and engineering groups throughout the company's United States, China, and India locations until his recent appointment to vice president of sales.
Source: Charles Ross & Son
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
